Analysts Set Expectations for Precigen FY2027 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Stock analysts at HC Wainwright dropped their FY2027 earnings estimates for Precigen in a note issued to investors on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings of $0.18 per share for the year, down from their prior forecast of $0.20. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s FY2028 earnings at $0.40 EPS and FY2029 earnings at $0.66 EPS.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research note on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $7.00.

Precigen Stock Performance

NASDAQ:PGEN opened at $1.80 on Friday. Precigen has a 52-week low of $0.65 and a 52-week high of $2.17. The business’s fifty day moving average is $1.60 and its 200 day moving average is $1.15. The firm has a market cap of $527.16 million, a price-to-earnings ratio of -3.27 and a beta of 1.58.

Precigen (NASDAQ:PGEN) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%. The business had revenue of $1.19 million during the quarter, compared to analyst estimates of $1.30 million.

Institutional Trading of Precigen

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in shares of Precigen in the 4th quarter worth approximately $27,000. Stifel Financial Corp boosted its stake in shares of Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 15,680 shares during the period. Envestnet Asset Management Inc. grew its holdings in shares of Precigen by 29.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 5,915 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in Precigen during the 4th quarter valued at $35,000. Finally, RPO LLC purchased a new position in shares of Precigen in the fourth quarter valued at about $47,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.